Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Hepatol Res. 2009 Oct;39(10):1020-2. doi: 10.1111/j.1872-034X.2009.00552.x.
The pulmonary complications of end-stage liver disease include hepatopulmonary syndrome and portopulmonary hypertension. The etio-pathogenesis of these conditions is as yet unclear. Hepatopulmonary syndrome is a gas exchange abnormality and usually manifests as hypoxemia secondary to intra-pulmonary vascular shunts. These shunts can be demonstrated by echocardiography using agitated saline injections, and quantitated by lung perfusion scans. Liver transplantation is the treatment of choice for hepatopulmonary syndrome, and there are no effective pharmacological therapies. Portopulmonary hypertension is a hemodynamic problem which manifests as fatigue and right sided cardiac failure. Several vasoactive agents have been used to lower mean pulmonary arterial pressures. Portopulmonary hypertension is a relative contraindication to liver transplantation.
终末期肝病的肺部并发症包括肝肺综合征和门肺高血压。这些病症的病因和发病机制尚不清楚。肝肺综合征是一种气体交换异常,通常表现为肺内血管分流引起的低氧血症。这些分流可以通过超声心动图用搅动盐水注射来显示,并通过肺灌注扫描来定量。肝移植是肝肺综合征的首选治疗方法,目前尚无有效的药物治疗方法。门肺高血压是一种血流动力学问题,表现为疲劳和右侧心力衰竭。已经使用了几种血管活性药物来降低平均肺动脉压。门肺高血压是肝移植的相对禁忌症。